Targeting adenosinergic pathway enhances the anti-tumor efficacy of sorafenib in hepatocellular carcinoma
ConclusionsThese results suggest that adenosinergic pathway might represent an applicable target for sorafenib-combined-therapies in human HCC.
Source: Hepatology International - Category: Infectious Diseases Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Genetics | Hepatocellular Carcinoma | Infectious Diseases | Liver Cancer | Transplants